Roche plans striking new Basel offices
pharmafile | January 4, 2010 | News story | Manufacturing and Production, Research and Development, Sales and Marketing | Basel, Roche, construction
Roche has unveiled plans for its new main office building in Basel, Switzerland, that will accommodate more than 1,800 people from its research, development, production, marketing and corporate functions.
“Roche needs a new office building in Basel”, commented Roche chief executive Severin Schwan. “We are convinced that having all the company’s departments close to each other will be crucial in ensuring that they work together successfully.”
The 41-storey ‘Building 1’ will cost approximately 550 million Swiss francs and will include an auditorium, cafeteria and a number of ‘communication zones’ for employees to use.
“The new building is a harmonious fit with the rest of our site and meets all our requirements in terms of functionality and engineering”, added Matthias Baltisberger, head of Roche’s site in Basel. “The new office building will enable us to offer our employees attractive workplaces and a top-quality infrastructure.”
The new building continues the predominantly white colour scheme that is typical of the Roche site in Basal and has also been adopted for the research and development building currently being built on Basel’s Wettsteinallee.
Both new buildings have been designed by Herzog and de Meuron and tie in with the architectural idiom defined by Otto Salvisberg, Roche said, adding that the new office building continues its longstanding tradition of high-quality industrial architecture.
Subject to gaining planning and development approval work on Building 1 will begin in 2012 and is due to be completed by 2015.
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
Lonza to acquire biologics site in Vacaville, US from Roche for $1.2bn
Lonza has announced that it has signed an agreement to acquire the Genentech large-scale biologics …
